MétaCan
Menu
← Back to cohort
Record W4416722133 · doi:10.1055/s-0044-1786882

Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy

2024· article· de· W4416722133 on OpenAlexaff
Bernhard Scheiner, Beodeul Kang, Lorenz Balcar, Iulian Radu, Florian P. Reiter, G. Adžić, Jiang Guo, Xu Gao, Xiaoyan Yuan, Long Cheng, Joao Gorgulho, Najib Ben Khaled, Maximilian Schultheiß, Friedrich Sinner, Katharina Pomej, Anna Saborowski, Birgit Schwacha‐Eipper, Valentina Zarka, Katharina Lampichler, Naoshi Nishida, P-C. Lee, A. Krall, Anum Saeed, Vera Himmelsbach, Giulia Tesini, Yuming Huang, C. Vivaldi, Gabriele Masi, Arndt Vogel, Kornelius Schulze, Michael Trauner, Rudolf Stauber, Masatoshi Kudo, Jeroen Dekervel, Neehar D. Parikh, Jean‐François Dufour, Juraj Prejac, Andreas Geier, Bertram Bengsch, Johann von Felden, Marino Venerito, A. Philipp, Fabian Finkelmeier, Feng Ji, Hung-Wei Wang, L. Rimassa, David J. Pinato, M. Bouattour, Hong Jae Chon, Matthias Pinter

Bibliographic record

VenueZeitschrift für Gastroenterologie · 2024
Typearticle
Languagede
FieldMedicine
TopicHepatocellular Carcinoma Treatment and Prognosis
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsHepatocellular carcinomaComplete responseSystemic therapyOutcome (game theory)CarcinomaRadiation therapy

Abstract

fetched live from OpenAlex

Background: The management and natural history of patients with hepatocellular carcinoma (HCC) who achieve complete response (CR) to immune checkpoint inhibitor (ICI)-based systemic therapies is not well described. Materials and methods: We conducted a retrospective study of adult patients with HCC who had CR to systemic ICI-based therapies from 18 centers in Europe and Asia. Results: Of 2502 patients with HCC treated with ICI, 123 patients (4.9%) achieved CR according to mRECIST (CR-mRECIST) and 72 patients (2.9%) had CR according to RECISTv1.1 (CR-RECISTv1.1) as well. 103 patients were male (84%), and the majority had BCLC stage C (n=87;71%) and Child-Pugh class A (n=112;91%). Median follow-up was 32.1 (95%CI,30.5-33.6) months.Median duration of CR (mRECIST) was 35.5 (95%CI, not estimable) months. Overall, 41 patients (33%) experienced recurrence a median of 11.4 months (95%CI, 8.9-14.0) after mRECIST CR. Recurrence rate was similar in patients with CR-mRECIST only (26%) and CR-RECISTv1.1 (39%; p=0.120), as were recurrence-free survival rates at one and two years (77% and 61% for CR-mRECIST only vs. 74% and 58% for CR-RECISTv1.1; p=0.310). A total of 93 patients (75.6%) discontinued ICI during follow-up due to adverse events (n=11, 11.8%), recurrence (n=15, 16.1%), durable CR (n=41, 44.1%), or other reasons (n=26, 28.0%). Among those who discontinued treatment for reasons other than recurrence (n=76), recurrence rate was 23.7% (n=18); patients who received systemic treatment for>6 months after complete response had a numerically lower recurrence rate (15.8%, n=6/38) compared to those who discontinued treatment earlier (31.6%, n=12/38; p=0.105). One-/3-/5-year overall survival (OS) rates of the whole cohort were 98%/88%/77%. Conclusions: Only a small proportion of patients with advanced HCC achieves CR to palliative immunotherapy, but these patients have an excellent overall survival. When considering ICI discontinuation, treatment for>6 months beyond CR may be associated with a lower recurrence rate. Publication History Article published online: 05 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.268
Teacher spread0.221 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractno

Explore more

Same venueZeitschrift für Gastroenterologie→Same topicHepatocellular Carcinoma Treatment and Prognosis→French-language works237,207→